Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,902 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The effectiveness of new triple combination therapy using synthetic disease-modifying anti-rheumatic drugs with different pharmacological function against rheumatoid arthritis: the verification by an in vitro and clinical study.
Hirai T, Ikeda K, Fujishiro M, Tsushima H, Hayakawa K, Suzuki S, Yamaguchi A, Nozawa K, Morimoto S, Takasaki Y, Ogawa H, Takamori K, Tamura N, Sekigawa I. Hirai T, et al. Among authors: yamaguchi a. Clin Rheumatol. 2017 Jan;36(1):51-58. doi: 10.1007/s10067-016-3458-8. Epub 2016 Oct 25. Clin Rheumatol. 2017. PMID: 27783236
Serum TNFα levels at 24 h after certolizumab pegol predict effectiveness at week 12 in patients with rheumatoid arthritis from TSUBAME study.
Miyazaki Y, Nakano K, Nakayamada S, Kubo S, Iwata S, Hanami K, Fukuyo S, Miyagawa I, Yamaguchi A, Kawabe A, Saito K, Tanaka Y. Miyazaki Y, et al. Among authors: yamaguchi a. Arthritis Res Ther. 2021 Jun 1;23(1):154. doi: 10.1186/s13075-021-02547-2. Arthritis Res Ther. 2021. PMID: 34074349 Free PMC article. Clinical Trial.
Selection of treatment regimens based on shared decision-making in patients with rheumatoid arthritis on remission in the FREE-J study.
Tanaka Y, Yamaguchi A, Miyamoto T, Tanimura K, Iwai H, Kaneko Y, Takeuchi T, Amano K, Iwamoto N, Kawakami A, Murakami M, Nishimoto N, Atsumi T, Sumida T, Ohmura K, Mimori T, Yamanaka H, Fujio K, Fujino Y, Saito K, Nakano K, Hirata S, Nakayamada S. Tanaka Y, et al. Among authors: yamaguchi a. Rheumatology (Oxford). 2022 Nov 2;61(11):4273-4285. doi: 10.1093/rheumatology/keac075. Rheumatology (Oxford). 2022. PMID: 35136990 Free PMC article.
Biological/targeted synthetic DMARDs do not arrest bone loss in patients with rheumatoid arthritis: a multicenter prospective observational study.
Sonomoto K, Nakayamada S, Fujino Y, Miyata H, Kubo S, Fujita Y, Inoue Y, Matsunaga S, Iwata S, Hanami K, Todoroki Y, Yoshinari-Korekoda H, Kawabe A, Yamaguchi A, Ueno M, Satoh-Kanda Y, Kanda R, Funada M, Ohkubo N, Kusaka K, Kosaka S, Nagayasu A, Fukuyo S, Nawata M, Miyazaki Y, Tokunaga M, Tanaka K, Okada Y, Tanaka Y. Sonomoto K, et al. Among authors: yamaguchi a. Rheumatology (Oxford). 2024 Aug 1;63(8):2239-2248. doi: 10.1093/rheumatology/kead579. Rheumatology (Oxford). 2024. PMID: 37934120
Efficacy, safety, and optimal intervention of belimumab for proliferative lupus nephritis patients in real-world settings: LOOPS registry.
Sakai H, Miyazaki Y, Nakayamada S, Kubo S, Hanami K, Fukuyo S, Yamaguchi A, Miyagawa I, Ueno M, Tanaka H, Todoroki Y, Ohkubo N, Funada M, Matsunaga S, Tanaka Y. Sakai H, et al. Among authors: yamaguchi a. Rheumatology (Oxford). 2024 Sep 17:keae495. doi: 10.1093/rheumatology/keae495. Online ahead of print. Rheumatology (Oxford). 2024. PMID: 39288317
Predictors of the effectiveness to first-line CTLA4-Ig in patients with rheumatoid arthritis: the FIRST registry.
Kobayashi H, Miyazaki Y, Nakayamada S, Hanami K, Fukuyo S, Kubo S, Yamaguchi A, Inoue Y, Todoroki Y, Miyata H, Tanaka H, Fujino Y, Hirata S, Tanaka Y. Kobayashi H, et al. Among authors: yamaguchi a. Rheumatology (Oxford). 2024 Nov 5:keae598. doi: 10.1093/rheumatology/keae598. Online ahead of print. Rheumatology (Oxford). 2024. PMID: 39499185
2,902 results